NCT00532675View on ClinicalTrials.gov

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 22, 2008

Primary Completion Date

November 8, 2017

Study Completion Date

November 8, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

LBH589

PAN 5 mg and PAN 20 mg capsules

COMBINATION_PRODUCT

Lenalidomide

Lenalidomide 5mg or 25 mg

Trial Locations (10)

3181

Novartis Investigative Site, Prahran

4101

Novartis Investigative Site, South Brisbane

10011

St. Vincent's Comprehensive Cancer Center, New York

30322

Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta

34295

Novartis Investigative Site, Montpellier

37007

Novartis Investigative Site, Salamanca

44035

Novartis Investigative Site, Nantes

46026

Novartis Investigative Site, Valencia

59037

Novartis Investigative Site, Lille

94143

UCSF Medical Center, San Francisco

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY